KEGG   DRUG: Sofosbuvir, velpatasvir and voxilaprevir
Entry
D10900            Mixture   Drug                                   
Name
Sofosbuvir, velpatasvir and voxilaprevir;
Vosevi (TN)
Product
VOSEVI (Gilead Sciences)
Component
Sofosbuvir [DR:D10366], Velpatasvir [DR:D10806], Voxilaprevir [DR:D10899]
Class
Antiviral
 DG03198  Anti-HCV agent
Remark
ATC code: J05AP56
Product: D10900<US>
Efficacy
Antiviral
  Disease
Chronic hepatitis C virus infection [DS:H00413]
Target
HCV NS3/4A protease [KO:K22273 K22274]
HCV NS5A [KO:K22275]
HCV NS5B [KO:K22472]
  Pathway
ko03230  Viral genome structure
ko03240  Viral replication
ko05160  Hepatitis C
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 J ANTIINFECTIVES FOR SYSTEMIC USE
  J05 ANTIVIRALS FOR SYSTEMIC USE
   J05A DIRECT ACTING ANTIVIRALS
    J05AP Antivirals for treatment of HCV infections
     J05AP56 Sofosbuvir, velpatasvir and voxilaprevir
      D10900  Sofosbuvir, velpatasvir and voxilaprevir <US>
USP drug classification [BR:br08302]
 Antivirals
  Anti-hepatitis C (HCV) Agents
   Sofosbuvir/ Velpatasvir/ Voxilaprevir
    D10900  Sofosbuvir, velpatasvir and voxilaprevir
Drug groups [BR:br08330]
 Antiviral
  DG03198  Anti-HCV agent
   D10900  Sofosbuvir, velpatasvir and voxilaprevir
Drug classes [BR:br08332]
 Antiviral
  DG03198  Anti-HCV agent
   D10900  Sofosbuvir, velpatasvir and voxilaprevir
Antimicrobials [BR:br08307]
 Antivirals
  Polyprotein cleavage inhibitor
   HCV NS3/4A inhibitor
    D10900  Sofosbuvir, velpatasvir and voxilaprevir <US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D10900
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D10900
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D10900
Other DBs
PubChem: 340650304
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system